- Home
- INCY vs FTI Comparison
INCY vs FTI Comparison
Compare INCY & FTI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INCY | FTI |
|---|---|---|
| Founded | 1991 | 1884 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.0B | 16.6B |
| IPO Year | 1993 | N/A |
Fundamental Metrics
Financial Performance| Metric | INCY | FTI |
|---|---|---|
| Price | $100.89 | $57.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 20 | 10 |
| Target Price | ★ $97.78 | $50.11 |
| AVG Volume (30 Days) | 2.0M | ★ 3.2M |
| Earning Date | 02-10-2026 | 02-19-2026 |
| Dividend Yield | N/A | ★ 0.35% |
| EPS Growth | ★ 3878.02 | 59.09 |
| EPS | ★ 5.90 | 2.28 |
| Revenue | $4,813,105,000.00 | ★ $9,803,000,000.00 |
| Revenue This Year | $19.64 | $10.35 |
| Revenue Next Year | $10.98 | $7.00 |
| P/E Ratio | ★ $17.39 | $24.75 |
| Revenue Growth | ★ 18.09 | 11.44 |
| 52 Week Low | $53.56 | $22.12 |
| 52 Week High | $112.29 | $56.93 |
Technical Indicators
Market Signals| Indicator | INCY | FTI |
|---|---|---|
| Relative Strength Index (RSI) | 47.03 | 84.00 |
| Support Level | $99.28 | $54.20 |
| Resistance Level | $105.06 | $56.93 |
| Average True Range (ATR) | 3.27 | 1.40 |
| MACD | -0.53 | 0.19 |
| Stochastic Oscillator | 24.25 | 99.29 |
Price Performance
Historical ComparisonAbout INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.
About FTI TechnipFMC plc
TechnipFMC is the largest provider of offshore oilfield services, offering integrated deep-water offshore oil and gas development solutions that span the full spectrum of subsea equipment and subsea construction services. The company also provides various pieces of surface equipment used with onshore oil and gas wells. TechnipFMC originated with the 2017 merger of Technip and FMC Technologies.